Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
28 févr. 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 févr. 2024 05h50 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter and year ended December 31, 2023, and provided a business update.
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
16 févr. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 févr. 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference
31 janv. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that Arcutis management will participate in the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference.
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
29 janv. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that JAAD published positive results from the pivotal Phase 3 STRATUM trial evaluating ZORYVE (roflumilast) foam, 0.3%.
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
22 janv. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the launch of ZORYVE® (roflumilast) topical foam, 0.3%, in the United States for the treatment of seborrheic dermatitis
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
14 janv. 2024 04h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new individual patient response data in Atopic Dermatitis with roflumilast cream according to new data from Phase 3 program
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
14 janv. 2024 04h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced a new subgroup analysis in adults and adolescents with seborrheic dermatitis from STRATUM study
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
15 déc. 2023 17h11 HE
|
Arcutis Biotherapeutics, Inc.
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration...